2018年起于北京大學(xué)腫瘤醫(yī)院從事胃腸腫瘤臨床工作及相關(guān)基礎(chǔ)研究。具有扎實(shí)的理論知識(shí)和一定的臨床技能；研究方向是胃腸腫瘤的早診、分子分型及個(gè)體化治療相關(guān)研究。

發(fā)表論文

XIE, M., DART, D. A., GUO, T., XING, X. F., CHENG, X. J., DU, H., JIANG, W. G., WEN, X. Z. & JI, J. F. 2018. MicroRNA-1 acts as a tumor suppressor microRNA by inhibiting angiogenesis-related growth factors in human gastric cancer. Gastric Cancer, 21, 41-54.

XIE, M., DART, D. A., OWEN, S., WEN, X., JI, J. & JIANG, W. 2016. Insights into roles of the miR-1, -133 and -206 family in gastric cancer (Review). Oncol Rep, 36, 1191-8.

XIE, M., HARGEST, R, JIANG, W., Meng Xie, JI, J., DART, D. A. 2018. Relationship of miR-140-5p expression and p53 function and contribution to prognosis prediction and treatment decision of patients with gastric cancer (Abstract). Journal of Clinical Oncology, 36, no. 15_suppl, e24185

XING, X., GUO, J., WEN, X., DING, G., LI, B., DONG, B., FENG, Q., LI, S., ZHANG, J., CHENG, X., GUO, T., DU, H., HU, Y., WANG, X., LI, L., LI, Q., XIE, M., LI, L., GAO, X., SHAN, F., LI, Z., YING, X., ZHOU, T., WANG, J. & JI, J. 2018. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology, 7, e1356144.

GUO, T., WEN, X. Z., LI, Z. Y., HAN, H. B., ZHANG, C. G., BAI, Y. H., XING, X. F., CHENG, X. J., DU, H., HU, Y., WANG, X. H., JIA, Y. N., NIE, M. L., XIE, M., LI, Q. D. & JI, J. F. 2019. ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7. Cell Death Dis, 10, 33.

JIANG, W., MARTIN, T. A., OWEN, S., YE. L., SANDERS, A., J., CUI Y., X., XIE, M., JIA, S., JIA, Y., RUGE F., AVOGADRI-CONNORS, F., LALANI A., BRYCE, R. JI J. Investigating the activity of neratinib in human gastric cancer and gastric cancer cells, implications on clinical outcome and chemotherapy resistance (Abstract 879). 2018. Cancer Research 78 (13 Supplement):879-879